Document text
Principal Investigator: Ignacio E. Sanz
Organization: EMORY UNIVERSITY
Fiscal Year: 2020
Award: $525,608
Funding agency: National Institute of Allergy and Infectious Diseases
The COVID19 pandemic illustrates the urgent need for understanding human B cell responses to emergent
pathogens and its application to assessing herd immunity. Our laboratories have described the phenotypic,
immunological and molecular features of different arms of human B cell responses and in particular, the original
characterization of the human extrafollicular effector B cell activation pathway and its contribution to different
memory and plasma cells responses. On that basis, we we propose to interrogate the different arms of the B cell
response to the SARS-CoV-2 virus; to identify the B cell compartments that participate in the early, ongoing and
late post-infection responses; and to determine their contribution to the establishment of herd immunity, at least
in part through the generation of protective B cell memory. The latter is an essential feature that could be
uncoupled from the persistence of serum antibodies; and therefore, would go unrecognized unless formally
tested. We postulate that the establishment of cellular B cell memory and the ability to evaluate its magnitude
and quality will be critical to track the risk of the population to short-term re-infection and seasonal exposure; to
design vaccines capable to trigger this protective feature; and to develop SARS-CoV-2 B cell-based diagnostic
tests. These goals will be accomplished using blood samples from SARS-CoV-2-infected and convalescent
individuals through the following specific aims: Aim 1. Characterization of SARS-CoV-2-specific B cell
responses through multidimensional B cell flow cytometry A precise adjudication of the cellular origin,
magnitude, and persistence of the anti-SARS-CoV-2 B cell response will be accomplished by antigen-specific
flow cytometry and validated by multiplex antigen assays and single cell analysis of the B cell populations. Aim
2. Measurement of SARS-CoV-2-specific B cell memory and herd immunity. Phenotypic features and
antigen-specific flow cytometry assays established in aim 1, will be applied to intermediate and late post-infection
time points in order to understand: a) the cellular compartments in which SARS-CoV-2-specific B cell memory
resides; b) its quality, magnitude and distribution within the population; c) its provenance (whether from early of
late cellular precursors); and d) its concordance or conversely, uncoupling from serological responses and the
generation of long-lived plasma cells (LLPC).
Terms: <2019 novel coronavirus><2019-nCoV><Address><Administrative Supplement><Affinity><Antibodies><Antibody Response><Antigens><Aspirate><Aspirate substance><Assay><Autoimmune Diseases><Autoimmune Status><Autoimmunity><B blood cells><B cell><B cells><B-Cell Activation><B-Cells><B-Lymphocytes><B-cell><Bioassay><Biologic Assays><Biological Assay><Blood Plasma Cell><Blood Sample><Blood Serum><Blood specimen><Bone Marrow><Bone Marrow Reticuloendothelial System><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Cell Body><Cell Compartmentation><Cell Compartmentations><Cells><Cellular Assay><Clinical Treatment Moab><Clinical Trials><Communities><Complement><Complement Proteins><Cooperative Agreements><Coronaviridae><Coronavirus><Development><Diagnostic tests><Disease><Disorder><Exposure to><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Funding><Gene Transcription><General Population><General Public><Generations><Genetic Transcription><Goals><Grant><Herd Immunity><Human><Immune memory><Immune response><Immunochemical Immunologic><Immunologic><Immunologic Memory><Immunological><Immunological Memory><Immunological response><Immunologically><Immunologics><Individual><Infection><Investigation><Knowledge><Laboratories><Laboratory Diagnosis><Length of Life><Link><Longevity><Lupus Erythematosus Disseminatus><MAb Therapeutics><Measurement><Measures><Medical><Memory><Memory B Cell><Memory B-Lymphocyte><Mice><Mice Mammals><Modern Man><Molecular><Molecular Evolution><Monoclonal Antibodies><Murine><Mus><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Parents><Pathway interactions><Patients><Phase><Phenotype><Plasma Cells><Plasmacytes><Population><RNA Expression><Regulation><Resolution><Risk><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><SLE><Serologic><Serological><Serum><Severe acute respiratory syndrome coronavirus 2><Systemic Lupus Erythematosus><Systemic Lupus Erythematous><Systemic Lupus Erythmatosus><T-Cells><T-Lymphocyte><TLR7><TLR7 gene><Testing><Therapeutic Monoclonal Antibodies><Time><Toll-Like Receptor 7><Transcription><U-Series Cooperative Agreements><United States National Institutes of Health><Vaccine Design><Vaccines><Viral><Virus><Work><Wuhan coronavirus><activated B cells><acute infection><adjudication><adjudicative process and procedure><anamnestic reaction><arm><autoimmune disorder><base><cell assay><clinical Diagnosis><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><cross reactivity><develop a vaccine><development of a vaccine><developmental><disseminated lupus erythematosus><flow cytophotometry><host response><immunogen><immunoresponse><life span><lifespan><mAbs><monoclonal antibody drugs><neutralizing mAb><neutralizing monoclonal antibodies><pathogen><pathway><plasmocyte><response><secondary immune response><single cell analysis><systemic lupus erythematosis><therapeutic mAbs><thymus derived lymphocyte><vaccine development><vaccine formulation>